Data Updates and Ongoing Trials in the HER2+ Adjuvant Space
July 13th 2023Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.
Treatment Guidelines on Fertility Preservation in Breast Cancer
Focused discussion on treatment guidelines and recommendations for fertility preservation while treating premenopausal patients with breast cancer.
Monitoring Patients With Breast Cancer Receiving OFS
A brief review of monitoring, response assessment, and treatment modification strategies used for patients with breast cancer undergoing OFS. .
BLU-945 Plus Osimertinib Has Favorable Tolerability, Warrants Further Development in EGFR+ NSCLC
July 7th 2023BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.
Earlier Use of Ide-Cel May Increase Benefit for Patients With High-Risk R/R Myeloma
July 6th 2023Krina K. Patel, MD, MSc, expands on the importance of evaluating outcomes for treatment with ide-cel in patients with relapsed/refractory multiple myeloma with different high-risk characteristics and key findings from the high-risk subgroup analysis of the KarMMa-3 trial.
Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen
July 6th 2023Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.
How Does Response to Neoadjuvant Therapy Affect Prognosis and Inform Adjuvant Selection?
July 6th 2023Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.
Factors Informing the Selection and Use of OFS in Breast Cancer
Expert perspectives on the appropriate selection and use of OFS in premenopausal patients with breast cancer.
Data From the SOFT and TEXT Trials: Combination Therapy With OFS in Breast Cancer
Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the SOFT and TEXT clinical trials to elucidate combination treatment strategies with ovarian function suppression (OFS).
Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.